Posts in Uncategorized

Auditing a Medical Device Quality System: ISO 13485, MDR Surveillance and the New QMSR

A medical device manufacturer selling into Europe and the United States is now audited against a quality system standard that both jurisdictions recognise. Since 2[…]

Building a Risk-Based Pharmacovigilance Audit Programme

Auditing your pharmacovigilance system is not optional and not a quality-department formality. It is a legal obligation on the marketing authorisation holder, its results are[…]

Validating Cloud and SaaS GxP Systems: Supplier Oversight and Shared Responsibility

Most regulated companies now run at least one GxP-critical process on software they do not host, cannot inspect directly, and cannot stop from updating. That[…]

Data Integrity and ALCOA+: Turning Audit Trail Review into a Real Control

Data integrity findings rarely arise because a company set out to falsify anything. They arise because nobody was looking. A system generates an audit trail,[…]

Computer Software Assurance: What FDA’s Final CSA Guidance Changes

For two decades, validating software used in production and quality systems meant generating documentation — often a great deal of it, and often with little[…]

Computerised System Validation: A Risk-Based Lifecycle That Survives Inspection

Almost every GxP decision a company makes today rests on data produced, stored or transformed by a computerised system. Regulators have responded by treating those[…]

Bioequivalence and the Generic Dossier: What ICH M13A Changed in the EU

A generic marketing authorisation application rests on a single scientific bridge: proof that your product behaves in the body the way the reference product does.[…]

Outsourced Activities and Quality Agreements: What EU GMP Chapter 7 Requires

Almost every pharmaceutical company outsources something — a manufacturing step, analytical testing, storage, transport, calibration, a hosted computerised system. What no company can outsource is[…]

Parallel Export and Shortage Notification in Greece: The Rules Behind the Ban List

Greece’s low reference prices make it an attractive place to buy medicines and a difficult place to keep them. EOF’s response is a rolling export[…]

Early Access in Greece: Reaching Patients Before Reimbursement

Between a European approval and a Greek reimbursement decision there is typically more than a year. Greece has a defined early access framework to bridge[…]